5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine manufacturers
- PKC-IN-1
-
- $198.00 / 2mg
-
2026-01-04
- CAS:1046787-18-1
- Min. Order:
- Purity: 98.79%
- Supply Ability: 10g
- PKC-IN-1
-
- $198.00 / 2mg
-
2025-04-30
- CAS:1046787-18-1
- Min. Order:
- Purity: 98.79%
- Supply Ability: 10g
|
| | 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine Basic information |
| Product Name: | 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine | | Synonyms: | 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine;PKC-IN-1;[(2S,5R)-2,5-Dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]methanone;CS-2112;Methanone, [(2S,5R)-2,5-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)methyl]-1-piperazinyl][3-[(5-fluoro-2-methyl-4-pyrimidinyl)amino]-4,6-dihydro-6,6-dimethylpyrrolo[3,4-c]pyrazol-5(1H)-yl]-;PKC,PKCIN1,PKC IN 1,Protein kinase C,inhibit,Inhibitor | | CAS: | 1046787-18-1 | | MF: | C25H37FN8O2 | | MW: | 500.61 | | EINECS: | | | Product Categories: | | | Mol File: | 1046787-18-1.mol | ![5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine Structure](CAS/20180808/GIF/1046787-18-1.gif) |
| | 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine Chemical Properties |
| Boiling point | 622.8±55.0 °C(Predicted) | | density | 1.253±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 25 mg/mL (49.94 mM) | | form | Solid | | pka | 14.13±0.40(Predicted) | | color | White to off-white |
| | 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine Usage And Synthesis |
| Uses | PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively. | | in vivo | PKC-IN-1 (Compound A; 15 and 30 mg/kg, p.o., bid (twice a day)) dose-dependently and significantly reduces maximum EAE severity and end severity in autoimmune encephalitis (EAE) model in Lewis rats[1]. | | IC 50 | Human PKCα: 2.3 nM (IC50); Human PKCβII: 7.6 nM (IC50); Human PKCβI: 8.1 nM (IC50); Human PKCθ: 25.6 nM (IC50); Human PKCγ: 57.5 nM (IC50); Human PKC mu: 314 nM (IC50); Human PKCε: 808 nM (IC50); Human PKCβ: 5.3 nM (Ki); Human PKCα: 10.4 nM (Ki) | | References | [1] Michael Niesman, et al. Treatment of autoimmune disease. WO2015179847A1. |
| | 5-{[(2S,5R)-2,5-dimethyl-4-(tetrahydro-2H-pyran-4-ylmethyl)piperazin-1-yl]carbonyl}-N-(5-fluoro-2-methylpyrimidin-4-yl)-6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-amine Preparation Products And Raw materials |
|